

NCT ID	NCT03190941
Title	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Phase	Phase 1, Phase 2
Date Added	2017-06-19
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT03170960
Title	Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2017-05-31
Location	Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium France Germany Italy Netherlands Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, Cabozantinib
Tags	MSS/ MMRp

NCT ID	NCT03155061
Title	Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Phase	Phase 1
Date Added	2017-05-16
Location	Japan
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	ONO-4538, ONO-4578, Opdivo
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03104439
Title	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Phase	Phase 2
Date Added	2017-04-07
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03096093
Title	Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Phase	Phase 1, Phase 2
Date Added	2017-03-30
Location	United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	ACIT-1
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03093116
Title	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase	Phase 1, Phase 2
Date Added	2017-03-28

Location	California, United States Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Australia Belgium Canada China Denmark France Germany Hong Kong Hungary Italy Japan Korea, Republic of Netherlands Poland Singapore Spain Taiwan United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Oral repotrectinib (TPX-0005)
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03088150
Title	COLLISION Trial – Colorectal Liver Metastases: Surgery vs Thermal Ablation
Phase	Phase 3
Date Added	2017-03-23
Location	Netherlands
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Unknown status
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03069469
Title	Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Phase	Phase 1, Phase 2

Date Added	2017-03-03
Location	California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	DCC-3014
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03030378
Title	Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
Phase	Phase 1
Date Added	2017-01-25
Location	California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Edodekin alfa, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03013218
Title	A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
Phase	Phase 1
Date Added	2017-01-06
Location	Colorado, United States Connecticut, United States Massachusetts, United States Michigan, United States Washington, United States Korea, Republic of
Prior IO Allowed	No
CRC-directed	No

Status	Active, not recruiting
Drugs	5-FU + Cisplatin, Evorpaccept (ALX148), Pembrolizumab, Ramucirumab + Paclitaxel, Rituximab, Trastuzumab
Tags	MSS/ MMRp